Biperiden pharmacological-MRI as a tool to assess the function of the central cholinergic system: a validation study

Biperiden pharmacological-MRI as a tool to assess the function of the central cholinergic system: a validation study - biperiden-phMRI

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43422

Enrollment

Registered

2016-03-29

Start date

2016-04-29

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

centrale cholinerge systeem NA

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - For men: age 40 years and older. For women: 50 years and older - Mentally competent to sign informed consent.

Exclusion criteria

Exclusion criteria: - Use of anticholinergic medication - Contraindications for MRI (e.g. metal implants, pacemaker etc.) - Severe neurological, endocrine or psychiatric disorders (e.g., depression, bipolar illness) - Pregnancy - Current use of recreational drugs; participants must have abstained from using recreational drugs such as cannabis for at least 4 weeks prior to participation. - Contraindications for biperiden - Contraindications for potassium iodide

Design outcomes

Primary

Measure	Time frame
- M1 receptor availability in the ACC, striatum and hippocampus. - Change in free choline concentrations in the ACC and striatum	—

Countries

Netherlands

Outcome results